-
It's High Time For Zynerba Positives: Investors Await 3 Key Mid-Stage Trial Reads On Cannabidiol ZYN002
Monday, March 27, 2017 - 4:07pm | 488Read More...Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) is about to embark upon a journey with unknown destinations, as investors brace for a trio of reads from the company in the third quarter of 2017. Focus: 3 Phase 2 Reads Of ZYN002 Cantor Fitzgerald said in a note released Monday it remains focused on...
